ExodusPoint Capital Management LP Raises Position in DexCom, Inc. (NASDAQ:DXCM)

ExodusPoint Capital Management LP boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 197.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 466,414 shares of the medical device company's stock after buying an additional 309,714 shares during the quarter. ExodusPoint Capital Management LP owned 0.12% of DexCom worth $36,273,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Versant Capital Management Inc purchased a new stake in shares of DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares during the period. TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC raised its position in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter worth $38,000. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 over the last 90 days. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the topic of several analyst reports. Citigroup lifted their target price on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $99.82.

DexCom Stock Up 1.4 %

DXCM stock traded up $0.88 during mid-day trading on Tuesday, reaching $62.51. The company had a trading volume of 1,957,819 shares, compared to its average volume of 4,112,526. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $141.99. The company has a market capitalization of $24.51 billion, a price-to-earnings ratio of 43.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a fifty day simple moving average of $79.63 and a 200 day simple moving average of $76.90.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.